MediWound Ltd.

MDWD Healthcare Biotechnology

MediWound Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.0 million, down 16.1% from fiscal 2024. In the quarter to June 2026, revenue fell 45.8%, EPS grew 53.7%, free cash flow fell 49.9% and total debt rose 51.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

11.85 0.36 −2.95%
Market cap
$157.6M
P/E
0.0×
Fwd P/E
−6.1×
Dividend yield
—
F-score
5/9
Altman Z
−1.05
Beneish M
−3.69
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
16.96 20.22 18.69 26.50 23.76 21.76 31.79 3.40 2.50 1.56
Revenue Growth
(16.14%) 8.22% (29.48%) 11.50% 9.19% (31.54%) 834.70% 36.26% 60.21% 159.23%
Cost of Revenue
13.71 17.59 15.11 13.33 14.99 14.22 11.85 2.09 1.58 2.16
Gross Profit
3.25 2.63 3.58 13.17 8.77 7.55 19.94 1.31 0.92 (0.60)
R&D Expenses
14.32 8.88 7.47 10.18 10.26 7.70 4.97 4.07 5.46 7.07
SG&A Expenses
14.21 13.14 11.61 10.65 9.74 8.69 9.31 7.99 9.14 12.49
Operating Income
(25.27) (19.40) (15.29) (8.34) (11.22) (8.84) 4.49 (3.96) (13.69) (20.15)
Non-operating Income/Expense
1.56 (10.76) 8.76 (11.18) (2.30) (0.44) (2.43) (1.70) (0.85) 1.27
Non-operating Interest Expenses
2.46 12.81 1.89 11.64 2.31 1.28 2.98 2.12 1.25 0.90
EBT
(23.71) (30.16) (6.53) (19.52) (13.52) (9.28) 2.07 (5.66) (14.53) (18.88)
Income Tax Provision
0.17 0.06 0.19 0.08 0.03 — — — — —
Income after Tax
(23.88) (30.22) (6.72) (19.60) (13.55) (9.28) 2.07 (5.66) (14.53) (18.88)
Dividends (Preferred)
— — — — — — — 0.00 — —
Net Income Common
(23.88) (30.22) (6.72) (19.60) (13.55) (9.20) 4.96 (1.06) (22.15) (18.88)
EPS (Basic)
(2.10) (3.03) (0.75) (3.93) (3.50) (2.38) 1.26 (0.28) (6.65) (6.02)
EPS (Diluted)
(2.10) (3.03) (0.75) (3.93) (3.50) (2.38) 1.26 (0.28) (6.65) (6.02)
Shares (Basic, Weighted)
11.38 9.96 9.01 4.99 3.89 3.89 3.88 3.87 3.34 3.12
Shares (Diluted, Weighted)
11.38 9.96 9.01 4.99 3.89 3.89 3.88 3.87 3.34 3.12
Gross Margin
19.19% 13.03% 19.15% 49.69% 36.91% 34.67% 62.73% 38.61% 36.78% (38.51%)
EBIT Margin
(148.98%) (95.94%) (81.83%) (31.50%) (47.22%) (40.62%) 14.13% (116.44%) (548.36%) (1,293.65%)
EBT margin
(139.81%) (149.16%) (34.95%) (73.68%) (56.91%) (42.62%) 6.50% (166.57%) (582.25%) (1,212.13%)
Net Profit Margin
(140.80%) (149.46%) (35.94%) (73.97%) (57.03%) (42.26%) 15.59% (31.08%) (887.38%) (1,212.13%)
Free Cash Flow Margin
(127.52%) (98.39%) (90.60%) (46.95%) (39.58%) (35.92%) 23.58% (373.07%) (702.32%) (1,100.51%)
EBITDA
(23.41) (17.92) (13.99) (7.07) (9.98) (7.75) 5.64 (3.38) (13.12) (19.57)
EBIT
(25.27) (19.40) (15.29) (8.34) (11.22) (8.84) 4.49 (3.96) (13.69) (20.15)
Income from Continuous Operations
(23.88) (30.22) (6.72) (19.60) (13.55) (9.28) 2.07 (5.66) (14.53) (18.88)
Income from Discontinued Operations
— — — — — 0.08 2.89 4.61 (7.62) —
Consolidated Net Income/Loss
(23.88) (30.22) (6.72) (19.60) (13.55) (9.20) 4.96 (1.06) (22.15) (18.88)
EPS (Basic, from Continuous Ops)
(2.10) (3.03) (0.75) (3.93) (3.48) (2.39) 0.53 (1.46) (4.36) (6.04)
EPS (Basic, from Discontinued Ops)
— — — — — 0.02 0.74 1.19 (2.28) —
EPS (Basic, Consolidated)
(2.10) (3.03) (0.75) (3.93) (3.48) (2.36) 1.28 (0.27) (6.64) (6.04)
EPS (Diluted, from Cont. Ops)
(2.10) (3.03) (0.75) (3.93) (3.48) (2.39) 0.53 (1.46) (4.36) (6.04)
EPS (Diluted, from Disc. Ops)
— — — — — 0.00 0.00 0.00 0.00 —
Shares (Diluted, Average)
11.38 9.96 9.01 4.99 3.89 3.89 3.88 3.87 3.34 3.12
EPS (Diluted, Consolidated)
(2.10) (3.03) (0.75) (3.93) (3.48) (2.36) 1.28 (0.27) (6.64) (6.04)
EBITDA Margin
(138.02%) (88.60%) (74.85%) (26.69%) (42.01%) (35.61%) 17.75% (99.47%) (525.64%) (1,255.84%)
Operating Cash Flow Margin
(95.06%) (67.37%) (56.00%) (44.86%) (37.52%) (31.68%) 26.08% (357.37%) (659.25%) (1,055.52%)

Fold the line items

In millions of $ except per-share values · columns are period end dates